posted
got the rest of my shares! I have a friend who was debating on which stock to buy on Friday,it was between GCCP and CLBE.....I think now she realized the mistake she made,she bought a boatload of GCCP in the .02's. I think our CLBE will be touching the .10's again soon,been in touch with Paul Knopick over the weekend and the outlook for CalbaTech is going to be great for all share holders!
Oct 17, 2005 (M2 PRESSWIRE via COMTEX) -- Today our stock watch alerts today include Featured Profile for VideoMovieHouse.com (OTCBB: VMHVF), SLS International, Inc. (AMEX: SLS) and stock alerts for Marmion Industries Corp. (OTCBB: MMIC), Hybrid Technologies Inc. (OTCBB: HYBT), CalbaTech, Inc. (OTCBB: CLBE), Lifestream Technologies, Inc. (OTCBB: LFTC)
CALBATECH, INC. (OTCBB: CLBE) "Up 26.32% in morning trading"
CalbaTech, Inc. (OTCBB: CLBE) is a publicly-traded incubator. CalbaTech incubates smaller, life science-based companies that are developing next generation products and technologies. The firm specifically sponsors companies that are capable of generating sales or licensing revenue within two years and require less than $1,000,000 to reach the market. It finances its acquisitions through a stock swap of a small percentage its own shares for 100% of the shares of the company being acquired.
check under Molecular applications division for the new DNA methods and the other sub catagories for just how much CalbaTech has going on.
check out the Cellular Therapy division for the iStem info.I am telling you they are connecting all the dots for one big outcome.
the research reagents is just icing on the cake!IMO buy and hold this and simply go away,let it sit and I think we all are in for a surprise in a month or two!
look under key personnel on the scientific advisory board,look at the credentials of these individuals,they are highly reckognized in their perspective fields and one even got a Nobel prize,these are highly motivated professionals in the field of success for biotechs!
Dr. Mullis received the Nobel Prize in chemistry in 1993, for his invention of the polymerase chain reaction (PCR). The process, which Dr. Mullis conceptualized in 1983, is hailed as one of the monumental scientific techniques of the 20th century, one that revolutionized genetic science and engineering. PCR has also been an enormous commercial success. The original patent was sold to Hoffman LaRoche for $300 million and has generated more than a billion dollars in revenue from royalties.
quote:Originally posted by hazel1401: should hit .06 tomorrow maybe a good time to get out until the next dip
You think this will take another dip before making significant gains? I suppose it probably will.. I bought in at around 0.075, so I'd hate to sell at a loss, but if this is going to drop again it'd be more monetarily sound to sell at 6 and then buy back in at 4 and THEN wait for the long haul ...
But I'm not sure.... That kind of thing is always such a tough call. With my recent luck, if I sell at a loss the stock is sure to double in price before I ever get a chance to buy back in
IP: Logged |
posted
I believe we will pass by .06 before another significant dip and .04 is history imo. If there is news then watch out..could be .1 before a pull back.
IP: Logged |
BUT YOU KNOW WHAT IF YOU BUY A STOCK AND IT GOES DOWN ITS AMISTAKE JUST TAKE FAULT FOR IT AND WITH THAT MONEY THATS LEFT TRY TO MAKE A LITTLE SOMETHING
DONT JUST SELL WHEN IT HITS 6, MONITOR IT AND TRY TO SELL AT THE DAYS HIGH IF ITS GOING UP AND STARTS GOING DOWN A LITTLE DOSENT MEAN NOTHING IT MIGHT GO EVEN HIGHER,JUST GO WITH YOUR GUT
-------------------- gotta make a grand AT LEAST daily man
IP: Logged |
posted
Ain't nothing like coming home from the Boot Hill Saloon (Daytona) and seeing we closed at the high of day!
As for .06,the last time we broke out like that we hit .10 quick so selling at .06 is a "NO NO" for me.This one is acting just as BIPH did in its early stages from .09,once it broke the last time it stayed on the climb and yes,it did make its dips,but buying back in was quite hard as it will be here.I am tellin you,buy and hold this one and put it away,I have been in contact with the company as recent as this past Saturday (yes Saturday,they even work on the weekend!..LOL)CalbaTech has a lot more going for them then many will realize until its to late and they will be chasing it.
Pro-Life Congressman and Dr. J Seek Adult Stem Cell Research Bill
Washington, DC (LifeNews.com) -- A leading pro-life congressman and former Philadelphia 76ers basketball star Julius "Dr. J" Erving teamed up at a press conference Thursday to ask the Senate to pass a House-approved bill that would promote adult stem cell research using umbilical cord blood. The bill provides funding to use stem cells from umbilical cord blood, which have proven to be the most effective and the House approved HR 2520 434-1 in May.
The Senate has stalled on voting for the bill because it has gotten caught up in the divisive debate over using taxpayer funds for embryonic stem cell research. Smith asked that the Senate not delay any further on voting on the bill.
"Delay is denial, especially for the sick who will not benefit from cord blood transplantation because the Senate inexplicably delayed," Smith said. "Make no mistake, for these sick children and adults, this is a matter of life or death."
Dr. J, who is currently the Vice President of the Orlando Magic, said African American patients need the bill to be approved because they have a much lower chance to obtain a match within the current bone marrow and umbilical cord blood stem cell inventories.
"Each year, thousands of Americans die who could be saved if larger and more diverse inventories of umbilical cord stem cells were in existence," Erving noted. "I came today to join Congressman Smith in asking the Senate to finish the job and pass this legislation and provide doctors the resources they need to treat the thousands of courageous patients in desperate need of help."
Currently, some minorities have less than a 50% chance of obtaining a potentially life saving transplant
Umbilical cords are a rich, non-controversial source of stem cells. Currently hospitals throw millions of them away each year because the infrastructure required to properly collect and store them is not available.
Thousands havebeen successfully treated with cord blood stem cells for more than 67 diseases including Leukemia and Sickle Cell Anemia.
The infusion of federal funds will make this medical miracle available to thousands more and will ensure that research continues so that this source of stem cells can treat many other debilitating diseases.
Numerous doctors and patients who have been treated with umbilical cord stem cells also attended the press conference.
Boswell backs adult stem cell research
Medical studies into embryonic stem cells have failed and it was time to get behind alternative research, Nationals Senate leader Ron Boswell says.
Three years ago, after a passionate debate, federal parliament passed laws giving scientists access to unwanted human embryos for research purposes.
Since then the national scientific regulator has issued nine licences for such research.
But Senator Boswell told parliament on Wednesday the research had come to nothing and support should now be given to alternative research on adult stem cells.
"The last debate was a very difficult one for many of us and led to deep searching over ethical issues involved," Senator Boswell told parliament.
"My point is that for all the pain we went through, for all the cost, we are not even close to the promised cures from embryo research.
"Yet there is true hope out there that medical research will tackle the most painful and debilitating diseases known to humanity and it will do it through adult stem cell technology.
"The only question is how long before the world wakes up to it.
"We have before us a sober opportunity to change direction to a zone of scientific research that is free of ethical dilemmas."
Senator Boswell said research had shown that adult stem cells provided a viable alternative to embryonic stem cells.
He said researchers at Queensland's Griffith University had successfully grown adult stem cells harvested from the olfactory mucosa, the organ of smell in the human nose.
They demonstrated the cells can give rise not only to nerve cells but also to heart, liver, kidney, and muscle cells.
The research team, led by Professor Alan Mackay-Sim has spent the past four years developing the research, particularly investigating the potential of stem cells in treating Parkinsons disease.
Senator Boswell's speech came as Industry Minister Ian Macfarlane was planning a forum for federal MPs next week to consider the issues surrounding stem-cell technologies.
Mr Macfarlane warned earlier this week that Australia's reputation as a global player in biotechnology could be undermined if conservative forces succeeded in banning embryonic stem-cell research.
CalbaTech, Inc., (CLBE) said its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, is acquiring a new facility that has two validated, Class 100 Clean Rooms for additional manufacture of products.
K-D Medical is a primary vendor to the National Institutes of Health (NIH) and currently sells products to every major pharmaceutical company in the U.S. K-D Medical's founder, John Powers, said the new Clean Rooms, plus a complete quality control laboratory, will allow the company to manufacture a higher quality product as well as expand the current custom product offering, better serving the needs of both existing and new customers.
"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers said.
"These new facilities allow K-D Medical to open new manufacturing and Clean Room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," said James DeOlden, chairman and CEO, CalbaTech. "We are very bullish on our subsidiary's future."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
NewsRx.com) -- CalbaTech, Inc., (CLBE) has retained the services of Agora Investor Relations Corp. (Agora).
The objective of this agreement is two-fold. First, to create effective communication between CalbaTech, its shareholders and the investment community through Agora's Internet based investor relations system. Effective immediately, a customized and monitored CalbaTech IR HUB will allow both CalbaTech and Agora to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications.
The IR HUB will also provide one-click access to the CalbaTech broker fact sheet, company profile, five most recent press releases, e-mail list registration, latest stock quote and chart information and an executive audio address updated quarterly. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the company that is free of spam, bashing, hyping and profanity.
Second, Agora will be fully responsible for creating, implementing and executing an investor relations strategy, the consolidation of which will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.
CalbaTech CEO James DeOlden stated, "We believe that the time is right to begin an investor awareness program. CalbaTech has been executing its business plan, and given the company's recent developments and the excitement being generated in the life sciences Industry, we believe the time has now come to significantly increase our communications with shareholders and the investment community."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
CalbaTech's business strategy is establish shareholder value by creating a significant new niche market by providing research reagents, equipment and services to the pharmaceutical research market, primarily through acquisition of life science companies that share the following attributes: 1) They will be generating revenues; 2) They will be profitable; and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products.
"The company reported that its outside patent counsel has conducted a preliminary patent review of the concepts and has reported favorable findings to CalbaTech's management. LifeStem, Dr. Van Tassel and outside counsel will work to further refine the intellectual property and expect to file provisional patents with the United States Patent Office".
Also the fact that the stock ran to .20 in july, expenses static around 1-mil, and this news out Thurs., is significiant, only it may take a few weeks for everyone to sort out.
posted
Thanks again for the DD and hard work, Quest! All I ask is if you hear something negative you'll let us know that as well, as I believe you would.
Hope you are enjoying Daytona... wish I was there!
IP: Logged |
posted
Reversal chart...MACD line need to break 0 first to run upward...Very interesting Chart because difficult to know where this stock is going in short term...need more buying pressure.
IP: Logged |
posted
looking good and I guess most already realize this is getting harder to buy any decent amount at a time without moving the B/A.This is going to be a great mid to long play.
posted
looking pretty strong now....a close over .06 would be nice,all it would take is a few small buys by investors who want to accumulate and hold mid to long.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Razz]](tongue.gif)
![[Big Grin]](biggrin.gif)
